Last reviewed · How we verify
NCT04593693
A Dual-center Study Evaluating Clinical Acceptance of a NPWT Wound Care System
NA trial testing Invia Motion Endure NPWT system in Diabetic Foot Ulcer in 25 participants. Completed in 18 May 2021.
18 May 2021
Quick facts
| Lead sponsor | Medela AG |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 25 |
| Start date | 10 December 2020 |
| Primary completion | 18 May 2021 |
| Estimated completion | 18 May 2021 |
| Sites | 2 locations across United States |
Drugs / interventions tested
- Invia Motion Endure NPWT system
Conditions studied
- Diabetic Foot Ulcer — all drugs for Diabetic Foot Ulcer →
- Pressure Injury — all drugs for Pressure Injury →
- Pressure Ulcer — all drugs for Pressure Ulcer →
- Surgical Wound — all drugs for Surgical Wound →
Sponsor
Medela AG
Who can join
18 and older, any sex, with Diabetic Foot Ulcer or Pressure Injury. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to determine if use of the Medela Invia Motion NPWT system supports acceptable progress towards the goal of therapy when treating patients with a variety of wound types during the evaluation period.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04593693
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Diabetic Foot Ulcer
Currently open trials in the same condition.
- NCT07161830 — Evaluating the Efficacy of OCM™ (Omeza® Complete Matrix) in the Treatment of Diabetic Foot Ulcers · NA · recruiting
- NCT07396376 — Evaluation of ELU42 Topical Spray for the Treatment of Diabetic Foot Ulcers · Phase 1, PHASE2 · recruiting
- NCT07291817 — Intermittent Negative Pressure for Patients With Diabetic Foot Ulcers (INPRESS) Study · NA · recruiting
- NCT07209358 — EDX110 Randomized Control Trial for Treatment of DFUs · NA · recruiting
- NCT06938685 — Evaluating the Efficacy NeoThelium FT in the Treatment of Diabetic Foot Ulcers · NA · recruiting
Other Medela AG trials
Trials by the same sponsor.
- NCT04619212 — Initiate Study Evaluating if Mothers Who Are Both Breastfeeding and Pumping in the First Days After Delivery Report Impr · NA · completed
- NCT03921918 — Evaluation of Fluid-Filled Expression Core Technology Study - I · NA · completed
- NCT03670225 — Evaluating Clinical Acceptance of a NPWT Wound Care System · NA · completed
- NCT03091985 — Influence of the Brownie Breast Shield on the Dynamics of Milk Removal · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04593693 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Medela AG
- Last refreshed: 24 September 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04593693.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing